thomas robert

nephrologist, MD, PhD, genetic kidney disease and rare kidney disease in Saint Joseph hospital and C2VN lab

[thomas robert @nephrobug]

Our paper in Joint Bone Spine shows the first link between a novel CNNM2 variant & early-onset CPPD.

The variant drives renal Mg wasting → chronic #hypomagnesemia. This expands the CNNM2 phenotype & urges genetic testing in atypical #CPPD.
https://t.co/R60CwTPEKp

[Mass General Brigham Research @MGBResearchNews]

Nephrologists! Check out this new series of review articles published by @MassGenBrigham researchers on genetic nephrology: https://t.co/PCFSqj4xKu @janewitwong @MGBKidneys

[thomas robert @nephrobug]

@MuellerRom Here our view from your response —>

[thomas robert @nephrobug]

The debate on #CKDx classification continues!
We’ve read the reply from the @ERAkidney G&K group. They champion simplicity over precision.
A thread 🧵:

[Abdulla A. Damluji, MD, PhD @DrDamluji]

🥸2️⃣0️⃣ These findings highlight the need for caution when considering aspirin for primary prevention in older adults. In this population, long-term use *may* not be associated with cardiovascular benefit and bleeding risks remain a concern.

[NDT @NDTsocial]

🎥Watch Dr Laurent Mesnard present the NDT publication:

CKDx is a good start - But can we go further?

https://t.co/VbYmaM4Xz2

[Daniel G. Fuster @Dan_Fuster]

Just out in Nature Reviews Nephrology.
Kidney stone disease: risk factors, pathophysiology and management.
https://t.co/u8izdfaLjZ

[thomas robert @nephrobug]

@gunnar_heine @NDTsocial —>

[thomas robert @nephrobug]

The debate on #CKDx classification continues!
We’ve read the reply from the @ERAkidney G&K group. They champion simplicity over precision.
A thread 🧵:

[NDT @NDTsocial]

🧐Read this interesting debate in NDT!

*CKDx: a necessary step—but can we go further?

🆓https://t.co/6bDJXgsqxn

*CKDx: simplicity matters, implementation is key

🆓https://t.co/6LM7jgTSYJ

[thomas robert @nephrobug]

Read their full response here: https://t.co/wQS2tnNJtX

[thomas robert @nephrobug]

The debate on #CKDx classification continues!
We’ve read the reply from the @ERAkidney G&K group. They champion simplicity over precision.
A thread 🧵:

[thomas robert @nephrobug]

3/ Quoting Osler seems wise. But be caution in applying 19th-century reasoning to 21st-century
Let's him in peace. 🕊️
They say: “Simplicity matters”
We say: “Ambiguity is not simplicity.”
#Nephrogenomics @com_SFNDT @FiliereORKiD @NDTsocial @ERAkidney @Laurent_Mesnard

[thomas robert @nephrobug]

@kdjhaveri @asnpublications 💡 Très bon article dans @asnpublications sur l’évolution de la gestion du potassium en #CKD : “Restricting the Restrictions” 🍌🥔
Des outils simples et visuels comme ces fiches pratiques peuvent aider patients et soignants à ajuster l’alimentation plutôt que de la restreindre.

[thomas robert @nephrobug]

💡 CKDx is a good start — but can we go further? 🔍

🚀 Exploring the strengths & limits of CKDx — and how we can push precision nephrology to the next level. @Laurent_Mesnard

🎥 https://t.co/JSAndXvoj5

🧬 #Nephrology | 🧪 #Genomics | 🎯 #PrecisionMedicine

[NDT @NDTsocial]

📽️Watch Dr Laurent Mesnard present the NDT publication:

CKDx is a good start - But can we go further?

https://t.co/VbYmaM4Xz2

[thomas robert @nephrobug]

@gunnar_heine @MuellerRom @ecorneclegall @Laurent_Mesnard @hjanders_hans @GlassockJ Fair point—G + A was never meant to replace “kidney insufficiency” in every ward note; it’s a dashboard for nephrologists. CKDx-r/e/t is the same: r0 e0 t1 just records “no deep work-up yet” and nudges us to escalate—our analogue of moving a case from G3A3 → G3A1.

[thomas robert @nephrobug]

CKDx: a necessary step—but can we go further? https://t.co/AAAxxM9xtD

[Nature Reviews Nephrology @NatRevNeph]

Nephrogenomics, precision medicine and the role of genetic testing in adult kidney disease management https://t.co/ldUda2XXfT